Document is current
Any future updates will be listed below
-
Authors
Szanto, Timea https://orcid.org/0000-0001-7006-6564
Lassila, Riitta https://orcid.org/0000-0002-1911-3094
-
Funding
Funding for this research was provided by:
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2024310)
University of Helsinki
- License Information
-
More Information
Article History
Received: 12 March 2026
Accepted: 31 August 2026
First Online: 25 September 2026
Declarations
Conflicts of interest: The authors declare the following interests during the past 3 years: TS received honoraria for advisory activities and lectures from CSL Behring, Octapharma, Pfizer, Roche, and Sobi. RL is the chief strategic officer (CSO) and chief medical officer (CMO) of Aplagon Ltd, a drug development company for thromboinflammatory diseases. She received honoraria for advisory activities and lectures from Biomarin, CSL Behring, LFB, Octapharma, Pfizer, Roche, Sanofi, Sobi, and Takeda.
Ethics approval: Not applicable.
Consent to participate: Not applicable.
Consent for publication: Not applicable.
Availability of data and material: Not applicable.
Code availability: Not applicable.
Artificial intelligence: ChatGPT has been occasionally used for language editing.
